Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Blood (2016) 128 (22): 177.

https://doi.org/10.1182/blood.V128.22.177.177

Published: 2016

Journal Articles

Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3 -ITDmutation

Maro Ohanian, DO, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Naval Daver, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Mark Brandt, BS, Sherry Pierce, BSN, BA, Jan Burger, MD PhD, Mary Ann Richie, Keyur Patel, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2016) 128 (22): 1611.

https://doi.org/10.1182/blood.V128.22.1611.1611

Published: 2016

Journal Articles

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Blood (2016) 128 (22): 234.

https://doi.org/10.1182/blood.V128.22.234.234

Published: 2016

Journal Articles

In Vivo Evidence of in Situ Cell Death Preferentially Occurring in CLL Patients with Minimal Lymphocytosis By the Diminished BCL2 and Loss of T Cell Support after Ibrutinib Treatment

Shih-Shih Chen, PhD, Steven Ham, Priyadarshini Ravichandran, Ileana D'Aloisio, Emily Kate Butera, Romi Lyallpuri, Yasmine Kieso, Jacqueline C. Barrientos, MD, Kanti R Rai, Jan Burger, MD PhD, Nicholas Chiorazzi, MD

Blood (2016) 128 (22): 5586.

https://doi.org/10.1182/blood.V128.22.5586.5586

Published: 2016

Journal Articles

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Susan M. O'Brien, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD PhD, Jan Burger, MD PhD, Kristie Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Jeffrey Jones, MD MPH, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Ying Luan, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, John C. Byrd, MD

Blood (2016) 128 (22): 233.

https://doi.org/10.1182/blood.V128.22.233.233

Published: 2016

Journal Articles

Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting

Prajwal Chaitanya Boddu, MD, Hagop M. Kantarjian, MD, Abdul Rashid Shah, MD, Gautam Borthakur, MD, Srdan Verstovsek, MD PhD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan Kadia, MD, Farhad Ravandi, MD, Nitin Jain, MD, Ahmad Alhuraiji, MD MRCP, Jan Burger, MD PhD, Steven M. Kornblau, MD, Sara Emogene Dellasala, BS, Sherry Pierce, BSN, BA, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 3073.

https://doi.org/10.1182/blood.V128.22.3073.3073

Published: 2016

Journal Articles

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Steven Coutre, MD, John C. Byrd, MD, Peter Hillmen, Jacqueline C. Barrientos, MD, Paul M. Barr, Stephen Devereux, PhD FRCP, FRCPath, Tadeusz Robak, MD PhD, Thomas J. Kipps, MD, PhD, Anna Schuh, MDPhD, Carol Moreno, MD, Richard R. Furman, Jan Burger, MD PhD, Michael O'Dwyer, MD, Paolo Ghia, Rudolph Valentino, PharmD, Samuel Suzuki, MS, MBA, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, Susan M. O'Brien, MD

Blood (2016) 128 (22): 4383.

https://doi.org/10.1182/blood.V128.22.4383.4383

Published: 2016

Journal Articles

Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib

Preetesh Jain, MBBS, MD DM, PhD, Philip A Thompson, MBBS, Michael Keating, MBBS, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Hagop M. Kantarjian, MD, Jan Burger, MD PhD, Susan M. O'Brien, MD, William G. Wierda, MD PhD

Blood (2016) 128 (22): 4390.

https://doi.org/10.1182/blood.V128.22.4390.4390

Published: 2016

Journal Articles

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Dan A. Landau, MD PhD, Clare Sun, MD, Daniel Rosebrock, Mariela Campbell, Sarah E. M. Herman, PhD, Julia Hoellenriegel, MS, Mohammed Farooqui, Wandi Zhang, MD, Donna S. Neuberg, ScD, Dimitri Livitz, Ignaty Leshchiner, Gad Getz, PhD, Jan Burger, MD PhD, Adrian Wiestner, MD PhD, Catherine J Wu, MD

Blood (2016) 128 (22): 188.

https://doi.org/10.1182/blood.V128.22.188.188

Published: 2016

Journal Articles

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2016) 128 (22): 2012.

https://doi.org/10.1182/blood.V128.22.2012.2012

Published: 2016

Journal Articles

Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

Princy Yohannan Sam, MD, Hycienth Ahaneku, MDPhD, Graciela M. Nogueras-Gonzalez, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, William G. Wierda, MD PhD, Naval Daver, MD, Tapan Kadia, MD, Jan Burger, MD PhD, Sherry Pierce, BSN, BA, Courtney D DiNardo, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 1919.

https://doi.org/10.1182/blood.V128.22.1919.1919

Published: 2016

Journal Articles

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Jennifer A. Woyach, MD, Peter Hillmen, Jennifer R. Brown, MD PhD, Steven E. Coutre, MD, Paul Barr, MD, Susan M. O'Brien, MD, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD FRCP, FRCPath, Neil E. Kay, MD, Nishitha Reddy, MD MSCI, MBBS, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Alessandra Tedeschi, Cathy Zhou, MS, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, John C. Byrd, MD, Jan Burger, MD PhD

Blood (2016) 128 (22): 2041.

https://doi.org/10.1182/blood.V128.22.2041.2041

Published: 2016

Journal Articles

CpG-Stimulated Cytogenetic Abnormalities Associated with Shorter Time-to-First Treatment

Francesco Paolo Tambaro, MD PhD, Clelia Criscuolo, MD, Nitin Jain, MD, Alessandra Ferrajoli, MD, Philip A Thompson, MBBS, Jan Burger, MD PhD, Zeev Estrov, MD, Mimmo Ripaldi, MD, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael Keating, MBBS, William G. Wierda, MD PhD

Blood (2016) 128 (22): 4351.

https://doi.org/10.1182/blood.V128.22.4351.4351

Published: 2016

Journal Articles

Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Farhad Ravandi, MBBS, Deborah Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Samuel Dara, MD, Rebecca Garris, BS, Partow Kebriaei, MD, Gautam Borthakur, MD, William Wierda, MD, PhD, Jan Burger, MD, Jorge Cortes, MD, Susan O’Brien, MD

Blood (2008) 112 (11): 2921.

https://doi.org/10.1182/blood.V112.11.2921.2921

Published: 2008

Journal Articles

Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL).

Stefan Faderl, MD, Deborah A. Thomas, MD, Varsha Gandhi, PhD MS BS, Gautam Borthakur, MD, Xuelin Huang, PhD, William Plunkett, PhD BS, Jan Burger, MD PhD, Jorge Cortes, MD, Susan O’Brien, MD, Farhad Ravandi, MD, Jennie Bretz, RN, Monica Kwari, RN, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 4335.

https://doi.org/10.1182/blood.V110.11.4335.4335

Published: 2007

Journal Articles

Single Center Experience with Philadelphia Chromosome-Positive Acute Myeloid Leukemia.

John Delmonte, Jr., MD, Hagop M. Kantarjian, MD, Elihu Estey, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Jan Burger, MD/PhD, Sherry Pierce, Jorge Cortes, MD

Blood (2007) 110 (11): 3505.

https://doi.org/10.1182/blood.V110.11.3505.3505

Published: 2007

Journal Articles

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Jennifer Cassat, Deborah Blamble, PHDP, B. Nebiyou Bekele, PhD, Miloslav Beran, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Jan Burger, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 2840.

https://doi.org/10.1182/blood.V110.11.2840.2840

Published: 2007

Journal Articles

Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

Jorge Cortes, MD, Susan O’Brien, MD, Elias Jabbour, MD, Alexandra Ferrajoli, MD, Gautam Borthakur, MD, Jan Burger, MD, William Wierda, MD, Guillermo Garcia-Manero, MD, Michelle Thomas, RN, Laurie Letvak, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 29.

https://doi.org/10.1182/blood.V110.11.29.29

Published: 2007

Journal Articles

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Farhad Ravandi, MD, Deborah Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Devri Brown, Rebecca Garris, Gautam Borthakur, MD, Jan Burger, MD, Partow Kebriaei, MD, Jeffrey Jorgensen, MD, Dan Jones, MD, Jorge Cortes, MD, Susan O’Brien, MD

Blood (2007) 110 (11): 2814.

https://doi.org/10.1182/blood.V110.11.2814.2814

Published: 2007

Journal Articles

Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs).

Elias Jabbour, MD, Hagop Kantarjian, MD, Dan Jones, MD, Susan O’Brien, MD, Guillermo Garcia-Manero, MD, Jan Burger, MD, Jorge Cortes, MD

Blood (2007) 110 (11): 1949.

https://doi.org/10.1182/blood.V110.11.1949.1949

Published: 2007

NARROW

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3 -ITDmutation

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

In Vivo Evidence of in Situ Cell Death Preferentially Occurring in CLL Patients with Minimal Lymphocytosis By the Diminished BCL2 and Loss of T Cell Support after Ibrutinib Treatment

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

CpG-Stimulated Cytogenetic Abnormalities Associated with Shorter Time-to-First Treatment

Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL).

Single Center Experience with Philadelphia Chromosome-Positive Acute Myeloid Leukemia.

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only